Core Insights - Zoetis (ZTS) received a positive opinion from the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) for its investigational monoclonal antibody therapy, Lenivia, aimed at relieving osteoarthritis pain in dogs [1][5][6] - The final decision from the European regulatory body is expected in Q4 2025, with a potential commercial launch in 2026 [2][9] - Lenivia is designed to provide pain relief for up to three months with a single injection, targeting nerve growth factor (NGF) [3][8] Company Developments - The approval of Lenivia would enhance Zoetis' leadership in the animal health sector and expand its innovative portfolio in companion animal therapeutics [6] - Lenivia will complement the existing product Librela, providing veterinarians and pet owners with both monthly and quarterly treatment options for managing osteoarthritis pain in dogs [5][8] - The company has also received a positive opinion for another monoclonal antibody therapy, Portela, for managing osteoarthritis pain in cats, which is expected to launch in 2026 if approved [9][11] Market Context - Osteoarthritis is a common condition affecting nearly 40% of dogs, leading to significant pain and reduced mobility [7] - The introduction of Lenivia and Portela could deepen Zoetis' penetration into the growing canine and feline osteoarthritis market, improving treatment adherence due to less frequent dosing schedules [11]